Myovant Sciences (MYOV) Files for $172.5M IPO
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Underwriters on the offering are Citigroup, Cowen and Company, Evercore ISI, and Barclays.
Myovant Sciences is a "clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders. Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist." The company continued, "We are advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Herbalife (HLF) Provides Q4, FY17 Guidance in Memorandum for $1.325B Credit Facility; Lowers FY17 Sales Guidance
- Ramaco (METC) Launches IPO of 6M Shares at a Price of $12-$15
- Morgan Stanley (MS), Citi (C) Each Fined ~$3M for False and Misleading Statements About Forex Trading
Create E-mail Alert Related CategoriesIPOs
Related EntitiesCiti, Barclays, Cowen & Co, IPO
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!